Trade Names:Bell/ans- Tablets 520 mg
Trade Names:Neut- Neutralizing additive solution 4% (0.48 mEq/mL)
Trade Names:Sodium Bicarbonate- Injection 4.2% (0.5 mEq/mL)- Injection 5% (0.6 mEq/mL)- Injection 7.5% (0.9 mEq/mL)- Injection 8.4% (1 mEq/mL)- Neutralizing additive solution 4.2% (0.5 mEq/mL)- Powder 120 g- Tablets 325 mg- Tablets 650 mg
Increases plasma bicarbonate; buffers excess hydrogen ion concentrations; raises blood pH; reverses metabolic acidosis.
Treatment of metabolic acidosis; promotion of gastric, systemic, and urinary alkalinization; replacement therapy in severe diarrhea; used to reduce incidence of chemical phlebitis (used as neutralizing additive solution).
Loss of chloride from vomiting or continuous GI suction when patient is receiving diuretics known to produce hypochloremic alkalosis; metabolic and respiratory alkalosis; hypocalcemia in which alkalosis may produce tetany, hypertension, convulsions, or CHF; when administration of sodium could be clinically detrimental.
IV Administration performed in concentrations ranging from 1.5% (isotonic) to 8.4% depending on clinical condition and requirements of patient.
Subcutaneous After dilution to isotonicity (1.5%). The dose depends on the clinical condition and requirements of the patient (including age and weight).
PO 325 mg to 2 g 1 to 4 times daily (patients younger than 60 yr of age, max dose 16 g/day; patients older than 60 yr of age max dose 8 g/day).Infants up to 2 yr of age
IV 4.2% solution at rate up to 8 mEq/kg/day.
Sodium bicarbonate can decrease elimination of these drugs, thus increasing their therapeutic effects.Chlorpropamide, lithium, methotrexate, salicylates, tetracyclines
Sodium bicarbonate can increase elimination of these drugs, thus decreasing their therapeutic effect.Ketoconazole
PO sodium bicarbonate may decrease the dissolution of ketoconazole in the GI tract, reducing the effectiveness.
Do not mix with IV solutions containing catecholamines, such as dobutamine, dopamine, and norepinephrine.
None well documented.
Exacerbation of CHF.
Rebound hyperacidity; milk-alkali syndrome.
Extravasation with cellulitis, tissue necrosis, ulceration, and sloughing; local pain; venous irritation; tetany; edema.
Category C .
Administration of at least 10 mL/min of hypertonic sodium bicarbonate may produce hypernatremia, decreased CSF pressure, and possible intracranial hemorrhage.
Use drug with caution in edematous sodium-retaining states, CHF, liver cirrhosis, toxemia of pregnancy, or renal impairment.
May be significant, especially in patients with hypertension or CHF or in patients on low-sodium diets.
Alkalosis, hyperirritability, tetany, nausea, vomiting.
Copyright © 2009 Wolters Kluwer Health.